Role of lipid apheresis in changing times

Clinical Research in Cardiology Supplements

Volumn 7, Issue SUPPL.1, 2012, Pages 7-14

  Schuff Werner, Peter ^a   Fenger, Sebastian ^a   Kohlschein, Peter ^a  

^a ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

Author keywords

Clinical effects and patient's outcome after LDL apheresis; Efficacy of LDL lowering; Future lipid lowering strategies; History of LDL apheresis; Longterm treatment

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN B; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANGIOGRAPHY; ARTICLE; ATHEROSCLEROTIC PLAQUE; COST BENEFIT ANALYSIS; FAMILIAL HYPERCHOLESTEROLEMIA; GENE SILENCING; GENE THERAPY; HUMAN; IMMUNE RESPONSE; IMMUNOADSORPTION; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; PLASMAPHERESIS; PLEIOTROPY; THERAPY EFFECT; APHERESIS; BLOOD; DISEASE COURSE; LIFESTYLE; METHODOLOGY; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ANTICHOLESTEREMIC AGENTS; BLOOD COMPONENT REMOVAL; CHOLESTEROL, LDL; DISEASE PROGRESSION; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIFE STYLE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84872176656     PISSN: 18610706     EISSN: 18610714     Source Type: Journal    
DOI: 10.1007/s11789-012-0049-3     Document Type: Article

References (56)

1. Abel IJ, Rowntree LG, Turner BB (1914) Plasma removal with return of corpuscles (plasmapheresis). J Pharmacol Exp Ther 5: 625-641.
2. Al-Allaf FA, Coutelle C, Waddigton SN, David AL, Harbottle R (2010) LDLR-gene therapy for familial hypercholesterolaemia: problems, progress, and perspectives. International Archives of Medicine 3: 36. http://www. intarchmed. com/content/3/1/36. Accessed 2 Jan 2012.
3. Armstrong VW, Windisch M, Wieland H, Fuchs C, Rieger J, Köstering H, Nebendahl K, Scheler F, Seidel D (1983) Selective continuous elimination of low-density lipoproteins with heparin at acidic pH. Trans Amer Soc Artif Intern Organs 29: 323-327.
4. Bosch T, Schmidt B, Blumenstein M, Gurland H-J (1993) Lipid apheresis by hemoperfusion: in vitro efficacy and ex vivo biocompatibility of a new low density lipoprotein adsorber compatible with human whole blood. Artif Organs 17: 640-652.
5. Bosch T, Schmidt B, Kleophas W, Gillen C, Otto V, Passlick-Deetjen J, Gurland HJ (1997) LDL-hemoperfusion-a new procedure for LDL apheresis: first clinical application of an LDL adsorber compatible with human whole blood. Artif Organs 21: 977-982.
6. Chen TS, Liou SY, Wu HC, Tsai FJ, Tsai CH, Huang CY, Chang YL (2011) Low-density lipoprotein (LDL) apheresis reduces atherogenic and oxidative markers in uremic patients with hyperlipidemia. Int Urol Nephrol 43: 471-474.
7. DeGennes JL, Touraine R, Maunand B, Truffert J, Laudat P (1967) Formes homozygotes cutanes-tendineuses de xanthomatose hypercholesterolemique dans une observation famiale exemplaire. Essai de plasmapherese a titre de traitment heroique. Bull Mem Soc Hop Paris 118: 1377-1402.
8. Dräger J, Petzhold S, Ristau H, Trepte S (2004) Internetbasierendes Qualitätsregister zur LDL-Apherese. In: Jäckel (ed) Telemedizinführer Deutschland. Ober-Mörlen, pp 242-244.
9. Eisenhauer T, Armstrong VW, Wieland H, Fuchs C, Scheler F, Seidel D (1987) Selective removal of low density lipoproteins (LDL) by precipitation at low pH: first clinical application of the HELP System. Klin Wschr 65: 161-168.
10. Geiss HC, Parhofer KG, Donner MG, Schwandt P (1999) Low density lipoprotein apheresis by membrane differential filtration (cascade filtration). Ther Apher 3: 199-202.
11. Goldstein JL, Brown MS (1973) Familial hypercholesterolemia: identification of a defect in the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity with overproduction of cholesterol. Proc Natl Acad USA 20: 2804-2806.
12. Greten H et al (1992) LDL-Apherese: Ein therapeutisches Verfahren bei schwerer Hypercholesterinämie. Dtsch Arztebl 89: 48-49.
13. Grossmann M, Rader DJ, Muller DW, Kolansky DM, Kozarsky K, Clark BJ III, Stein EA, Lupien PJ, Brewer HP Jr, Raper SE, Wilson JM (1995) A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolemia. Nat Med 1: 1148-1154.
14. Julius U, Siegert G, Gromeier S (2000) Intraindividual comparison of the impact of two selective apheresis methods (DALI and HELP) on the coagulation system. Int J Art Organs 23: 199-206.
15. Kamath BM, Oldhoff KM (2010) Liver transplantation in children: update 2010. Pediatr Clin North Am 57: 401-414.
16. Kastelein JJP, Wedel MK, Baker BF, Su J, Bradley JD, Yu RZ, Chuang E, Graham MJ, Crooke RTL (2006) Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 114: 1729-1735.
17. Kitabatake A, Sato H, Hori M, Kamada T, Kubori S, Hoki N, Minamino T, Yamada M, Kato T (1994) The Osaka LDL-apheresis multicenter trial group. Coronary atherosclerosis reduced in patients with familial hypercholesterolemia after intensive cholesterol lowering with low-density lipoprotein-apheresis: 1 year follow-up study. Clin Ther 16: 416-428.
18. Knisel W, Di Nicuolo A, Pfohl M, Müller H, Risler T, Eggstein M, Seifried E (1993) Different effects of two methods of low-density lipoprotein apheresis on the coagulation and fibrinolytic systems. J Intern Med 234: 479-487.
19. Kroon AA, Aengevearen WRM, van Der Werf T, Uijen GJH, Reiber JHC, Bruschke AVG, Stalenhoef AFH (1996) The LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid-lowering treatment on coronary atherosclerosis. Circulation 93: 1826-1835.
20. Lennertz A, Parhofer KG, Samtleben W, Bosch T (1999) Therapeutic plasma exchange in patients with chylomicronemia syndrome complicated by acute pancreatitis. Ther Apher 3: 227-233.
21. Lupien PJ, Moorjani S, Lou M, Brun D, Gagne C (1980) Removal of cholesterol from blood by affinity binding to heparin-agarose: evaluation of treatment in homozygous familial hypercholesterolemia. Ped Res 14: 113-117.
22. Maiorana A, Nobile V, Calandra S, Francalanci P, Bernabei S, El Hachem M, Monti L, Gennari F, Torre G, de Ville de Goyet J, Bartuli A (2011) Preemptive liver transplantation in a child with familial hypercholesterolemia. Pediatr Transplantation 15: E25-E29.
23. Mellwig KP, Baller D, Gleichmann U, Moll D, Betker S, Weise R, Notohamiprodjo G (1998) Improvement of coronary vasodilatation capacity through single LDL apheresis. Atherosclerosis 139: 173-178.
24. Napoli C, Ambrosio G, Scarpato N, Corso G, Palumbo G, Armiento FP, Mancini FP, Malorni A, Formisano S, Ruocco A, Cali A, Chiarello M (1997) Decreased low-density lipoprotein oxidation after repeated selective apheresis in homozygous familial hypercholesterolemia. Am Heart J 133: 585-595.
25. Nishimura S, Sekiguchi M, Kano T, Ishiwata S, Nagasaki F, Nishide T, Okimoto T, Kutsumi Y, Kuwabara Y, Takatsu F, Nishikawa H, Daida H, Yamaguchi H (1999) Effects of intensive lipid lowering by low-density lipoprotein apheresis on regression of coronary atherosclerosis in patients with familial hypercholesterolemia: Japan low-density lipoprotein apheresis coronary atherosclerosis prospective study (L-CAPS). Atherosclerosis 144: 409-417.
26. Nosé Y, Usami M, Malchesky PS, Emura M, Horiuchi T, Sakamoto H, Smith JW (1985) Clinical thermofiltration: initial application. Artif Organs 9: 425-427.
27. Pfammatter JP, Stocker FP, Oetliker O, Wiesmann U, Meier B (1996) Familial hypercholesterolemia with severe cardiac involvement in a boy: successful management and mid-term follow-up. Acta Paediatr 85: 254-257.
28. Pokrovsky SN, Sussekov AV, Afanasieva OI, Adamova IY, Lyakishev AA, Kukharchuk VV (1994) Extracorporeal immunoadsorption for the specific removal of lipoprotein(a) (Lp(a) apheresis): preliminary clinical data. Chem Phys Lipids 67-68: 323-330.
29. Raper A, Kolansky DM, Cuchel M (2011) Treatment of familial hypercholesterolemia: is there a need beyond statin therapy? Curr Atheroscler Rep Dec 2 (Epub ahead of print).
30. Richter WO, Donner MG, Hofling B, Schwand P (1998) Long-term effect of low-density lipoprotein apheresis on plasma lipoproteins and coronary heart disease in native vessels and coronary bypass in severe heterozygous familial hypercholesterolemia. Metabolism 47: 863-868.
31. Rubba P, Iannuzzi A, Postiglione A, Scarpato N, Montefusco S, Gnasso A, Nappi G, Cortese C, Mancini M (1990) Hemodynamic changes in the peripheral circulation after repeat low-density lipoprotein apheresis in familial hypercholesterolemia. Circulation 81: 610-616.
32. Saal SD, Parker TS, Gordon BR et al (1986) Removal of low-density lipoproteins in patients by extracorporeal immunoadsorption. Am J Med 80: 583-589.
33. Scheel AK, Schettler V, Koziolek M, Koelling S, Werner C, Müller GA, Strutz F (2004) Impact of chronic LDL-apheresis treatment on Achilles tendon affection in patients with severe familial hypercholesterolemia: a clinical and ultrasonographic 3-year follow-up study. Atherosclerosis 174: 133-139.
34. Schettler V, Jaeger BR, Klingel R, German apheresis working group (2009) The German lipid apheresis registry-remaining to be established. Atheroscler Suppl 10: 59-61.
35. Schuff-Werner P, Schütz E, Seyde WC, Eisenhauer T, Jannings G, Armstrong VW, Seidel D (1989) Improved haemorheology associated with a reduction in plasma fibrinogen and LDL in patients being treated by heparin-induced extracorporeal LDL precipitation (HELP). Eur J Clin Invest 19: 30-37.
36. Schuff-Werner P, Gohlke H, Bartmann U, Baggio G, Corti MC, Dinsebacher A, Eisenhauer T, Grützmacher P, Keller C, Kettner U et al (1994) The HELP-LDL-apheresis multicentre study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. II. Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concentrations and the course of coronary heart disease. The HELP-Study Group. Heparin-induced extracorporeal LDL precipitation. Eur J Clin Invest 24: 724-732.
37. Schuff-Werner P (2003) Langzeitergebnisse mit der H. E. L. P.-Apherese. Z Kardiol 92: III28-29.
38. Schwab PJ, Fahey IL (1960) Treatment of Waldenström's macroglobulinemia by plasmapheresis. N Engl J Med 263: 574-579.
39. Stefanutti C, Vivenzio A, Ferraro PM, Claudia M, Dany B (2011) Apheresis-inducible cytokine pattern change in severe genetic dyslipidemias. Cytokine 56(3): 835-841 (Epub 2011 Sep 14).
40. Stegmayr B, Ptak J, Wikström B (2007) World apheresis registry report. Tranf Apher Sci 36: 13-16.
41. Stoffel W, Greve V, Borberg H (1981) Application of specific extracorporeal removal of low-density lipoprotein in familial hypercholesterolemia. Lancet II: 1005-1007.
42. Tamai O, Matsuoka H, Itabe H, Wada Y, Kohno K, Imaizumi T (1997) Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 95: 76-82.
43. Tatami R, Inoue N, Itoh H, Kishino B, Koga N, Nakashima Y, Nishide T, Okamura K, Saito Y, Teramoto T (1992) Regression of coronary atherosclerosis by combined LDL-apheresis and lipid-lowering drug therapy in patients with familial hypercholesterolemia: a multicenter study. The LARS investigators. Atherosclerosis 95: 1-13.
44. Tatami R, Inoue N, Itoh H, Kishino B, Koga N, Nakashima Y, Nishide T, Okamura K, Saito Y, Teramoto T, Yasugi T, Yamamoto A, Goto Y (1992) Regression of coronary atherosclerosis by combined LDL-apheresis and lipid-lowering drug therapy in patients with familial hypercholesterolemia: a multicenter study. Atherosclerosis 95: 1-13.
45. Thiery J (1988) Maximaltherapie der Hypercholesterinämie bei koronarer Herzkrankheit. Kombination einer Plasmatherapie (HELP) mit HMG-CoA-Reduktasehemmern. Therapiewoche 38: 3424-3437.
46. Thomas CE, Ehrhardt A, Kay MA (2003) Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 4: 346-358.
47. Thompson GR, HEART-UK LDL Apheresis Working group (2008) Recommendations for the use of LDL apheresis. Atherosclerosis 198: 247-255.
48. Thompson GR, Lowenthal R, Myant NB (1975) Plasma exchange in the management of homozygous familial hypercholesterolemia. Lancet I: 1208-1211.
49. Thompson GR, Maher VM, Matthews S, Kitano Y, Neuwirth C, Shortt MB, Davies G, Rees A, Mir A, Prescott RJ, de Feyter P, Henderson A (1995) Familial hypercholesterolemia regression study: a randomized trial of low-density lipoprotein apheresis. Lancet 345: 811-816.
50. Thompson GR, Miller JP, Breslow JL (1985) Improved survival of patients with homozygous familial hypercholesterolemia treated by plasma exchange. Br Med J 291: 1671-1673.
51. Von Baeyer H, Schwerdtfeger R, Schwarzkopf W, Schurig R, Kochinke F, Marx M, Schutten D (1983) Selective removal of low density lipoprotein (LDL) by plasmapheresis combined with selective plasma-protein ultrafiltration (SPU). Plasma Ther Tranfus Technol 4: 447-458.
52. Waidner T, Franzen D, Völker W et al (1994) The effect of LDL-apheresis in progression of coronary artery disease in patients with familial hypercholesterolemia. Results of a multicenter LDL-apheresis study. Clin Investig 72: 858-863.
53. Wieland H, Seidel D (1983) A simple specific method for precipitation of low density lipoproteins. J Lipid Res 24: 904-909.
54. Würzner R, Schuff-Werner P, Franzke A, Nitze R, Oppermann M, Armstrong VW, Eisenhauer T, Seidel D, Götze O (1991) Complement activation and depletion during LDL-apheresis by heparin-induced extracorporeal LDL-precipitation (HELP). Eur J Clin Invest 21: 288-294.
55. Yokoyama S, Hayashi R, Kikkawa T, Tani N, Takada S, Hatanaka K, Yamamoto A (1984) Specific sorbent of apolipo-protein B-containing lipoproteins for plasmapheresis. Arteriosclerosis 4: 276-282.
56. Zwiener RJ, Uauy R, Petruska ML, Huet BA (1995) Low-density lipoprotein apheresis as long-term treatment for children with homozygous familial hypercholesterolemia. J Pediatr 126: 728-735.